BGB-53038 for Cancer
Trial Summary
What is the purpose of this trial?
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as monotherapy in participants with advanced or metastatic solid tumors harboring KRAS mutations or amplification, as well as when used in combination with tislelizumab (also known as BGB-A317) in participants with nonsquamous non-small cell lung cancer (NSCLC) and used in combination with cetuximab in participants with colorectal cancer (CRC). The study consists of 2 phases: Phase 1a Dose Escalation and Safety Expansion and Phase 1b Dose Expansion.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, since the trial involves new cancer treatments, it's possible that some medications might need to be adjusted. Please consult with the trial coordinators or your doctor for specific guidance.
What data supports the idea that BGB-53038 for Cancer is an effective treatment?
The available research shows that immune checkpoint blockade (ICB) therapy, which includes treatments like BGB-53038, is associated with significantly improved survival in patients with advanced solid tumors compared to those who did not receive ICB therapy. Additionally, patients with certain genetic profiles, such as a high tumor mutation burden (TMB), tend to have better outcomes with ICB treatments. This suggests that BGB-53038 can be effective, especially for patients with specific genetic markers. However, the effectiveness can vary based on individual genetic factors.12345
What safety data is available for BGB-53038 (Cetuximab) in cancer treatment?
The provided research does not contain specific safety data for BGB-53038 (Cetuximab) or its related names. The studies focus on other cancer treatments like olaparib, veliparib, and prexasertib, as well as immune checkpoint inhibitors combined with bevacizumab. For safety data on BGB-53038, you may need to consult clinical trial registries or specific studies on Cetuximab.678910
Is the drug BGB-53038 a promising treatment for cancer?
Yes, BGB-53038, which is related to the protein 53BP1, shows promise as a cancer treatment. Research indicates that 53BP1 can suppress tumor growth, especially in breast cancer, by helping repair damaged DNA and preventing cancer cells from spreading. This makes it a potential target for new cancer therapies.1112131415
Eligibility Criteria
This trial is for adults with advanced solid tumors like colorectal, gastric, or lung cancer that have specific KRAS mutations or amplifications. Participants need to be in good physical condition (ECOG ≤ 1), able to provide a tumor sample, and have at least one measurable lesion. They must also have proper organ function and agree to use effective birth control.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 1a: Dose Escalation and Safety Expansion
Sequential cohorts will be evaluated to determine the Recommended Dose for Expansion (RDFE) of BGB-53038 as a monotherapy and in combination with other therapies.
Phase 1b: Dose Expansion
Participants will receive BGB-53038 at the RDFE(s) as monotherapy or in combination with tislelizumab or cetuximab.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BGB-53038 (Small Molecule Inhibitor)
- Cetuximab (Monoclonal Antibodies)
- Tislelizumab (Monoclonal Antibodies)